GRAIL, Inc. (GRAL) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, GRAIL reported revenue of $147.2M, up 17.2% from $125.6M the year before. Net income was -$408.4M (a -277.5% net margin), or -$11.11 per diluted share. Gross margin was -382.0% and operating margin was -382.0%. Operating activities generated -$299.0M of cash, leaving -$299.9M of free cash flow. At fiscal year end, GRAIL held $2.92B in total assets against $344.2M in total liabilities, including $249.7M of cash and equivalents.
Open the full interactive GRAIL financials → Quarterly statements, key ratios, valuation history and price charts.
GRAIL Key Stats
| Share Price | $140.35 |
|---|---|
| Market Cap | $6.05B |
| Revenue YoY Growth | +17.2% |
| 52-Week Range | $43.03 – $154.08 |
| Shares Outstanding | 43.1 million (basic, 2026 Q2) |
GRAIL Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $125.6M | $147.2M |
| Cost of Goods Sold | $2.31B | $709.3M |
| Gross Profit | -$2.19B | -$562.2M |
| Operating Income | -$2.19B | -$562.2M |
| Pre-Tax Income | -$2.16B | -$534.5M |
| Income Tax | -$135.4M | -$126.2M |
| Net Income | -$2.03B | -$408.4M |
| Diluted EPS | -$63.54 | -$11.11 |
GRAIL Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $36.2M | $43.6M | $40.8M | $44.7M |
| Net Income | -$89.0M | -$99.2M | -$93.2M | -$110.2M |
| Diluted EPS | -$2.46 | -$2.70 | -$2.29 | -$2.56 |
GRAIL Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $214.2M | $249.7M |
| Current Assets | $819.9M | $953.8M |
| Total Assets | $2.98B | $2.92B |
| Current Liabilities | $76.9M | $79.7M |
| Total Liabilities | $479.9M | $344.2M |
| Shareholders' Equity | $2.50B | $2.58B |
GRAIL Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$577.2M | -$299.0M |
| Cash From Investing | -$551.0M | -$85.0M |
| Cash From Financing | $1.24B | $423.3M |
| Free Cash Flow | -$582.4M | -$299.9M |
Figures from GRAIL's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full GRAIL financials page for every line item.
GRAIL Company Profile
| Ticker | GRAL |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Sunnyvale, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, emerging growth company |
| SEC CIK | 0001699031 |
Frequently Asked Questions
What was GRAIL's revenue in fiscal 2025?
GRAIL (GRAL) reported revenue of $147.2M for fiscal 2025.
What was GRAIL's net income in fiscal 2025?
GRAIL reported net income of -$408.4M for fiscal 2025.
What was GRAIL's earnings per share (EPS) in fiscal 2025?
GRAIL's diluted EPS was -$11.11 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did GRAIL generate in fiscal 2025?
GRAIL generated -$299.9M of free cash flow in fiscal 2025.
What was GRAIL's revenue last quarter?
In its most recent reported quarter (2026 Q2), GRAIL reported revenue of $44.7M.
How many shares of GRAIL are outstanding?
GRAIL reported a weighted average of 43.1 million basic shares outstanding in 2026 Q2.
What is GRAIL's market cap?
Based on its latest closing price, GRAIL (GRAL) has a market capitalization of about $6.05B.
When does GRAIL's fiscal year end?
GRAIL's fiscal year end, as registered with the SEC, is December 31.
Where is GRAIL headquartered?
GRAIL lists its business address in Sunnyvale, California in its SEC filings.